CEL-SCI receives regulatory clearance to expand phase III head and neck cancer trial
CEL-SCI announced that Turkey's Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection). July 22, 2014